Zusammenfassung
Die Psoriasis ist eine der weltweit am häufigsten vorkommenden chronischen, entzündlichen Hauterkrankungen mit einer Inzidenz von 0,5–3 %. Historisch wurde sie lange Zeit als eine nicht juckende Hauterkrankung beschrieben. Diese Ansicht hat sich in den letzten Jahren jedoch grundlegend gewandelt. Mittlerweile ist anerkannt, dass 64–97 % der an Psoriasis erkrankten Patienten unter auch teilweise massivem Pruritus leiden. Dies führt neben der Belastung durch die Psoriasis selbst zu zusätzlich negativem Stress und einer deutlichen Einschränkung der Lebensqualität. Ätiologisch spielt bei der Entstehung des Pruritus bei Psoriasis neben anderem eine neurogene Entzündung eine wichtige Rolle. Darin involviert sind zahlreiche Neuropeptide wie Substanz P, „calcitonin gene related peptide“ und viele andere, die als Mediatoren fungieren. Parallel dazu scheint auch ein gestörtes Gleichgewicht zwischen κ‑ und µ‑Opioid-Rezeptoren in den Läsionen ätiologisch wichtig zu sein. Therapeutisch kommt es nach einer klinisch kompletten Abheilung der Psoriasisläsionen zu einem Verschwinden des Pruritus. Somit konzentrieren sich bis heute antipruritische Therapien eher auf die klinische Behandlung der Psoriasis. In besonders schweren Fällen des Pruritus bei Psoriasis kann zusätzlich eine gezielt antipruritische Therapie erwogen werden, wie z. B. mit oralen Antidepressiva (Mirtazapin, Doxepin und andere), Neuroleptika (Pregabalin, Gabapentin) und Präparaten, die in das κ‑ und µ‑Opioid-Rezeptor-Gleichgewicht eingreifen. Parallel mit der Einführung zahlreicher antipsoriatischer Substanzen in den letzten Jahren ist das Interesse an der Erforschung und Therapie des Pruritus bei Psoriasis deutlich gestiegen und wird erfreulicherweise im Rahmen der neuen therapeutischen Möglichkeiten auch gezielt wissenschaftlich untersucht.
Abstract
Psoriasis is a common chronic inflammatory disease with an incidence of about 0.5–3 %. Previously psoriasis was not primarily regarded to be associated with pruritus; however, this perception has changed in recent years. Meanwhile data conclusively show that between 64 and 97 % of patients report about pruritus that can be severe in a number of cases. Apart from suffering from psoriasis, the presence of pruritus causes additional stress and leads to a significant impairment of health-related quality of life. Neurogenic inflammation at least in part contributes to the development of pruritus in psoriasis skin lesions. A number of neuropeptides including substance P and calcitonin gene related peptide can act as pro-inflammatory mediators. There is evidence for a dysbalance between κ‑ and µ‑opioid receptors in lesional skin favoring inflammation and pruritus. After clearing of psoriasis lesions, pruritus is relieved as well. Therefore, specific treatment of pruritus is not necessary in general. In cases where severe pruritus is a prominent symptom, targeted therapy with mirtazapin or doxepin or neuroleptic compounds such as pregabalin or gabapentin or drugs affecting the κ‑ und µ‑opioid receptor balance can be administered. Today the importance of pruritus as a prominent symptom of psoriasis lesions has been widely accepted. In recent and running clinical trials with new drugs, pruritus at baseline and the effect of these drugs on pruritus is always assessed. This awareness also fuels basic research about pruritus in psoriasis.
Literatur
Al’Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ (1995) Neuropeptides and general neuronal marker in psoriasis – an immunohistochemical study. Clin Exp Dermatol 20(5):384–389
Amatya B, Wennersten G, Nordlind K (2008) Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 22(7):822–826
Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C et al (2009) Opioids and the skin – where do we stand? Exp Dermatol 18(5):424–430
Bilac C, Ermertcan AT, Bilac DB et al (2009) The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol 75(5):551
Chan J, Smoller BR, Raychauduri SP et al (1997) Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 289(11):611–616
Chang SE, Han SS, Jung HJ et al (2007) Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 156(6):1272–1277
Dawn A, Yosipovitch G (2006) Treating itch in psoriasis. Dermatol Nurs 18(3):227–233
Eedy DJ, Johnston CF, Shaw C et al (1991) Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J Invest Dermatol 96(4):434–438
Glinski W, Brodecka H, Glinska-Ferenz M et al (1994) Neuropeptides in psoriasis: possible role of beta-endorphin in the pathomechanism of the disease. Int J Dermatol 33(5):356–360
Gowda S, Goldblum OM, McCall WV et al (2010) Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 63(1):114–123
Griffiths CE, Reich K, Lebwohl M et al (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993):541–551
Gupta G, Long J, Tillman DM (1999) The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 140(5):887–890
Gupta MA, Gupta AK, Kirkby S et al (1988) Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 124(7):1052–1057
Hawi A, Alcorn H Jr, Berg J et al (2015) Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 16:47
He Y, Ding G, Wang X et al (2000) Calcitonin gene-related peptide in Langerhans cells in psoriatic plaque lesions. Chin Med J 113(8):747–745
Hrehorów E, Salomon J, Matusiak L et al (2012) Patients with psoriasis feel stigmatized. Acta Derm Venereol 92(1):67–72
Jiang WY, Raychaudhuri SP, Farber EM (1998) Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 37(8):572–574
Kimball AB, Edson-Heredia E, Zhu B, Guo J et al (2016) Understanding the relationship between pruritus severity and work productivity in patients with moderate-to-severe psoriasis: sleep problems are a mediating factor. J Drugs Dermatol 15(2):183–188
Kou K, Nakamura F, Aihara M et al (2012) Decreased expression of semaphorin-3 A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm Venereol 92(5):521–528
Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10
Mrowietz U, Chouela EN, Mallbris L et al (2015) Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol 29(6):1114–1120
Nakamura M, Toyoda M, Morohashi M (2003) Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 149(4):718–730
Narbutt J, Olejniczak I, Sobolewska-Sztychny D et al (2013) Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res 305(3):191–195
Naukkarinen A, Harvima I, Paukkonen K et al (1993) Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 285(6):341–346
Nigam R, El-Nour H, Amatya B et al (2010) GABA and GABA(A) receptor expression on immune cells in psoriasis: a pathophysiological role. Arch Dermatol Res 302(7):507–515
O’Neill JL, Chan YH, Rapp SR et al (2011) Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. Acta Derm Venereol 91(5):537–540
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377–385
Prignano F, Ricceri F, Pescitelli L et al (2009) Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol 19(2):9–13
Raychaudhuri SP, Farber EM (2001) The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15(1):16–17
Raychaudhuri SP, Jiang WY, Farber EM (1998) Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 78(2):84–86
Reich A, Szepietowski JC (2014) Chapter 4, clinical aspects of itch: psoriasis. In: Carstens E, Akiyama T, Itch (Hrsg) Mechanisms and treatment. Frontiers in Neuroscience. CRC Press, Taylor & Francis, Boca Raton
Reich A, Szepietowski JC, Wisnicka B, Pacan P (2003) Does stress influence itching in psoriatic patients? Dermatol Psychosom 4:151–155
Reich A, Orda A, Wiśnicka B, Szepietowski JC (2007) Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol 16(5):421–428
Reich A, Wójcik-Maciejewicz A, Slominski AT (2010) Stress and the skin. G Ital Dermatol Venereol 145(2):213–219
Reich A, Hrehorów E, Szepietowski JC (2010) Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 90(3):257–263
Reich A, Welz-Kubiak K, Szepietowski JC (2011) Pruritus differences between psoriasis and lichen planus. Acta Derm Venereol 91(5):605–606
Remröd C, Lonne-Rahm S, Nordlind K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res 299:85–91
Revicki D, Willian MK, Saurat JH et al (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158(3):549–557
Revicki DA, Willian MK, Menter A et al (2007) Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 18(6):341–350
Roblin D, Yosipovitch G, Boyce B et al (2015) Topical TrkA Kinase inhibitor CT327 is an effective, novel therapy for the treatment of Pruritus due to psoriasis: Results from experimental studies, and efficacy and safety of CT327 in a Phase 2b clinical trial in patients with Psoriasis. Acta Derm Venereol 95(5):542–548
Saeki H, Nakagawa H, Ishii T et al (2015) Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29(6):1148–1155
Sampogna F, Gisondi P, Melchi CF et al (2004) IDI multipurpose psoriasis research on vital experiences investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 151(3):594–599
Saraceno R, Kleyn CE, Terenghi G et al (2006) The role of neuropeptides in psoriasis. Br J Dermatol 155(5):876–882
Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352(18):1899–1912
Sobell JM, Foley P, Toth D et al (2016) Effects of Apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 96(4):514–520
Staniek V, Doutremepuich J, Schmitt D et al (1999) Expression of substance P receptors in normal and psoriatic skin. Pathobiology 67(1):51–54
Steinhoff M, McGregor GP, Radleff-Schlimme A et al (1999) Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept 80(1–2):49–55
Strober B, Sigurgeirsson B, Popp G et al (2016) Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol 55(4):401–407
Szepietowski JC, Reich A (2016) Pruritus in psoriasis: an update. Eur J Pain 20(1):41–46
Szepietowski JC, Reich A, Wiśnicka B (2002) Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 10(4):221–226
Tae-Wook K, Woo-Haing S, Joung-Min K et al (2014) Clinical characteristics of pruritus in patients with scalp psoriasis and their relation with Intraepidermal nerve fiber density. Ann Dermatol 26(6):727–732
Taneda K, Tominaga M, Negi O et al (2011) Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol 165(2):277–284
van de Kerkhof PC, Reich K, Kavanaugh A et al (2015) Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and Psoriatic arthritis survey. J Eur Acad Dermatol Venereol 29(10):2002–2010
van Os-Medendorp H, Guikers CL, Eland-de Kok PC et al (2008) Costs and cost-effectiveness of the nursing programme „Coping with itch“ for patients with chronic pruritic skin disease. Br J Dermatol 158(5):1013–1021
Verhoeven EW, Kraaimaat FW, de Jong EM et al (2009) Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 161(2):295–299
Wiśnicka B, Szepietowski JC, Reich A, Orda A (2004) Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis. Dermatol Psychosom 5:73–78
Yosipovitch G, Goon A, Wee J et al (2000) The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 143(5):969–973
Zamirska A, Reich A, Berny-Moreno J et al (2008) Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol 88(2):132–135
Zimolag I, Reich A, Szepietowski JC (2009) Influence of psoriasis on the ability to work. Acta Derm Venereol 89:575–576
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Tsianakas: Beratertätigkeit für Biogen-IDEC, Celgene, Leo, Novartis, Pfizer. U. Mrowietz war in den zurückliegenden 3 Jahren als honorierter Berater und/oder Redner und/oder Empfänger von Forschungsunterstüzungen und/oder Teilnehmer an klinischen Studien für folgende Firmen tätig: Abbott/AbbVie, Almirall-Hermal, Amgen, BASF, Biogen Idec, Boehringer-Ingelheim, Celgene, Centocor, Eli Lilly, Foamix, Forward Pharma, Galderma, Janssen, Leo Pharma, Medac, MSD, Miltenyi Biotech, Novartis, Pfizer, Teva, VBL, Xenoport.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Tsianakas, A., Mrowietz, U. Pruritus bei Psoriasis. Hautarzt 67, 601–605 (2016). https://doi.org/10.1007/s00105-016-3835-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-016-3835-x